IL2 and cancer: To investigate the mechanisms affecting IL-2-mediated expansion of tumour-reactive TILs in patients with cancer, we took advantage of coupled single-cell RNA-sequencing (scRNA-seq) and single-cell T cell receptor sequencing (scTCR-seq) analyses conducted in a clinical protocol of TIL-ACT therapy in patients with melanoma11 (Fig. 1a).